on this topic, o1 pro demo finding a protein that matches a bunch of requirements is pretty cool
@nathanbenaich
-
AI Scientists Collaborate in Virtual Laboratory Using LLMs
By
–
“Researchers have created a virtual laboratory staffed by ‘AI scientists’ — LLMs with defined scientific roles — that collaborate to achieve goals set by people. The team trained one LLM to be the work’s principal investigator (PI) and a second to act as a ‘scientific critic’.
-
Government procurement reform drives startup investment and scaling
By
–
they will come, if investors actually start wiring cash which will happen, if govs actually buy shit from startups with real sizeable contracts which will happen, if they have literally no other option but to do so or if procurement reform happens.
-
Technology’s Role in Solutions: Exploring Innovation Opportunities
By
–
Either way, the conversation needs to evolve rapidly and we need to explore the role of technology in any potential solution. If you’re working on something interesting – get in touch!
-
Biological Design Policy Proposals and Their Evolution
By
–
The most detailed proposals we’ve seen come from @kesvelt
, but they were published in November 2022. A short-time in traditional policy, a long time in biological design tool evolution. -
Community efforts addressing foundational AI questions and challenges
By
–
So what should we do? It’s been great to see the community coming together to start answering some of these questions, with some of the top names in the field taking these questions seriously. But much of the de novo-focused work remains high level.
-
AI assistance remains challenging despite potential benefits
By
–
AI might help them, but it’s still a big ask.
-
Governments Need Closer Dialogue with AI Experts
By
–
Unfortunately, based on what we’ve seen – governments don’t seem very interested. Governments spend far too little time talking to people like @AnEmergentI
, only acting when it’s too late. -
Governing AI Models: Frameworks for Responsible Development
By
–
We’re seeing work like this from @tessafyi
, @mslkmp
, @samuelmcurtis and co. setting out frameworks for responsibly governing BDTs. These are eminently sensible and industry should likely adopt them, but there are lingering questions about how to tackle de novo threats -
Regulating Specialist Biodesign Tools: Beyond Compute Thresholds
By
–
The story’s different when it comes to specialist biodesign tools – going back to our DNA synthesis scenario at the top. But the regulatory approaches that may work for big frontier labs (e.g. compute thresholds) don’t translate so well for these. The scale/capability